Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) COO Sells $80,777.88 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) COO Stuart A. Arbuckle sold 306 shares of the business’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $263.98, for a total transaction of $80,777.88. Following the sale, the chief operating officer now directly owns 64,760 shares of the company’s stock, valued at $17,095,344.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vertex Pharmaceuticals stock opened at $273.70 on Thursday. The stock has a market capitalization of $69.94 billion, a PE ratio of 30.31, a price-to-earnings-growth ratio of 1.87 and a beta of 0.55. Vertex Pharmaceuticals Incorporated has a twelve month low of $176.36 and a twelve month high of $292.75. The company has a quick ratio of 4.30, a current ratio of 4.46 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $259.65 and a 200-day moving average of $228.62.

Several institutional investors have recently added to or reduced their stakes in the company. Camden National Bank boosted its holdings in Vertex Pharmaceuticals by 73.0% during the fourth quarter. Camden National Bank now owns 27,395 shares of the pharmaceutical company’s stock worth $6,474,000 after purchasing an additional 11,561 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Vertex Pharmaceuticals by 19.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 24,613 shares of the pharmaceutical company’s stock worth $4,465,000 after purchasing an additional 4,047 shares during the last quarter. Lincoln National Corp boosted its holdings in Vertex Pharmaceuticals by 24.0% during the third quarter. Lincoln National Corp now owns 1,271 shares of the pharmaceutical company’s stock worth $231,000 after purchasing an additional 246 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vertex Pharmaceuticals by 5.1% during the third quarter. PNC Financial Services Group Inc. now owns 31,140 shares of the pharmaceutical company’s stock worth $5,649,000 after purchasing an additional 1,524 shares during the last quarter. Finally, Calton & Associates Inc. acquired a new position in Vertex Pharmaceuticals during the third quarter worth $213,000. Institutional investors own 89.84% of the company’s stock.

VRTX has been the subject of a number of recent research reports. Oppenheimer boosted their price target on shares of Vertex Pharmaceuticals from $305.00 to $350.00 in a research note on Monday, April 4th. Wells Fargo & Company boosted their price target on shares of Vertex Pharmaceuticals from $270.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 5th. Piper Sandler boosted their price target on shares of Vertex Pharmaceuticals from $245.00 to $249.00 and gave the stock a “neutral” rating in a research note on Thursday, April 21st. Royal Bank of Canada downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $269.00 price target for the company. in a research note on Thursday, February 3rd. Finally, Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $279.00 price target for the company. in a research note on Monday, April 4th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $273.43.

Vertex Pharmaceuticals Company Profile (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

See Also

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.